Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Geron Gains Merck Milestone for Cancer Vax IND | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Geron Gains Merck Milestone for Cancer Vax IND

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck has filed an IND with the FDA for a cancer vaccine candidate that targets telomerase. Merck is developing the vaccine under a July, 2005 Research, Development and Commercialization License Agreement with Geron Corp., which provided exclusive worldwide rights to develop and commercialize non-dendritic cell-based vaccines targeting telomerase. Geron received a $4 million milestone payment from Merck after the IND filing, and is eligible to receive additional development milestones as well as royalties on worldwide product sales.

“We are pleased with the progress that Merck has made in advancing this program towards the clinic,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and chief executive officer. “We appreciate the collaborative nature of our relationship with Merck and look forward to working with them to realize the therapeutic potential of this cancer vaccine candidate.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters